ADMINISTRATION OF EXOGENOUS ERYTHROPOIETIN β AFFECTS LIPID PEROXIDATION AND SERUM PARAOXONASE-1 ACTIVITY AND CONCENTRATION IN PREDIALYSIS PATIENTS WITH CHRONIC RENAL DISEASE AND ANAEMIA

SUMMARY 1 Patients with advanced chronic renal disease and anaemia have decreased serum paraoxonase‐1 (PON1) activity and an increased degree of oxidative stress compared with normal subjects. The present study investigated the effects of treatment of anaemia with exogenous recombinant erythropoieti...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental pharmacology & physiology 2007-04, Vol.34 (4), p.347-349
Main Authors: Marsillach, Judit, Martínez-Vea, Albert, Marcas, Luis, Mackness, Bharti, Mackness, Michael, Ferré, Natàlia, Joven, Jorge, Camps, Jordi
Format: Article
Language:English
Subjects:
Aged
Anemia - blood
Anemia - complications
Anemia - drug therapy
Antibodies - blood
Aryldialkylphosphatase - blood
Dose-Response Relationship, Drug
erythropoietin
Erythropoietin - administration & dosage
Erythropoietin - therapeutic use
Female
Ferric Compounds - administration & dosage
Ferric Compounds - therapeutic use
Glucaric Acid
Hemoglobins - analysis
Humans
Injections, Intravenous
Injections, Subcutaneous
Kidney Failure, Chronic - blood
Kidney Failure, Chronic - complications
Kidney Failure, Chronic - therapy
lipid peroxidation
Lipid Peroxidation - drug effects
Lipoproteins, LDL - immunology
Lipoproteins, LDL - metabolism
Male
Middle Aged
Oxidative Stress - drug effects
paraoxonase-1
Recombinant Proteins
Renal Dialysis
renal disease
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:SUMMARY 1 Patients with advanced chronic renal disease and anaemia have decreased serum paraoxonase‐1 (PON1) activity and an increased degree of oxidative stress compared with normal subjects. The present study investigated the effects of treatment of anaemia with exogenous recombinant erythropoietin (EPO) β and iron on levels of antibodies against oxidized low‐density lipoproteins (ox‐LDL), as well as on serum PON1 activity and concentration, in predialysis patients with chronic renal disease. 2 Forty‐nine patients with chronic renal failure and haemoglobin (Hb)
ISSN:0305-1870
1440-1681
DOI:10.1111/j.1440-1681.2007.04552.x